TB-500
A synthetic fragment related to thymosin beta-4, studied for cell migration, actin regulation, and tissue-repair pathways.
What TB-500 is
TB-500 is a synthetic research peptide associated with the actin-binding region of thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid peptide abundant in platelets and wound fluid. In laboratory and preclinical models, Tβ4 and related fragments have been examined for roles in cell motility, angiogenesis, inflammation resolution, and extracellular-matrix organization after injury.
Researchers study TB-500 because full-length Tβ4 has a long experimental record in dermal wound models, cardiac injury paradigms, corneal repair work, and regenerative-biology reviews. The synthetic fragment is used as a more practical research tool when investigators want to probe actin-cytoskeleton and repair-associated signaling without working with the entire native protein.
All material discussed here is Research Use Only (RUO). It is not a drug product, not approved by the FDA for human use, and not intended for human consumption, clinical treatment, or diagnostic procedures. Published dosage figures below are literature or commonly cited research-protocol references, not recommendations.
Nearly all of the published work on TB-500 is preclinical: animal models and cell studies. Human evidence is thinner than the volume of online discussion suggests.
How it works
Thymosin beta-4 sequesters G-actin and helps regulate actin polymerization, which influences cytoskeletal remodeling and cell migration. Related domains have been linked in the literature to pro-angiogenic signaling, reduced inflammatory tone at injury sites, and shifts in fibrosis-related cell phenotypes. TB-500 is studied as a compact surrogate for key actin-binding and repair-associated activities of the parent peptide, though fragment-versus-full-length differences remain an active research question.
Who works with it, and what they are measuring
Interest is highest among regenerative-biology, sports-medicine research, and wound-healing laboratories that model soft-tissue injury, angiogenesis, or cytoskeletal control of repair. Comparative work also appears in cardiac and corneal injury literature focused on Tβ4 biology rather than TB-500 as a clinical agent.
What the research examines
Research areas, not results. A topic on this list is being studied, not settled.
How it appears in the literature
Figures as they appear in the source literature. Context matters more than the number.
| Research context | Reported amount | Frequency | Route |
|---|---|---|---|
| Commonly cited in research-protocol summaries for synthetic TB-500 | 2 mg – 5 mg | twice weekly | subcutaneous |
| Maintenance-style ranges reported in research-community protocols | 2 mg – 2.5 mg | once weekly | subcutaneous |
| Human intravenous Tβ4 safety study (full-length peptide, not TB-500 fragment) | 42 mg – 1260 mg | single or daily multi-dose cohorts | intravenous |
Handling & storage
Keep lyophilized vials refrigerated or frozen, protected from light and moisture. After reconstitution with bacteriostatic water, refrigerate and use within the timeframe specified by the laboratory protocol, typically days to a few weeks.
Notes on combined research
In research discussions, TB-500 is frequently examined alongside BPC-157 because both appear in soft-tissue repair literature, though through different proposed pathways. Some protocols also pair actin-repair work with growth-hormone secretagogue or GHRH-analog models when the experimental question involves recovery physiology rather than a single molecular target.
TB-500 questions
Secondary research summaries most often cite about 2,000-5,000 mcg twice weekly during higher-intensity phases, with lower once-weekly amounts afterward. These are reference figures from protocol literature, not medical advice.
Not exactly. TB-500 is a synthetic peptide related to the actin-binding region of thymosin beta-4. Full-length Tβ4 is the native 43-amino-acid peptide used in many primary papers.
Research vials of 5-10 mg are commonly reconstituted with 2-3 mL bacteriostatic water so insulin-syringe graduations map cleanly to mcg amounts. Exact solvent volume depends on the assay design.
Most interest centers on actin sequestration, cell migration, angiogenesis, and inflammation-resolution signaling observed with Tβ4-family peptides in injury models.
No. Research-grade TB-500 is sold for laboratory Research Use Only. It is not an FDA-approved drug and is not for human consumption or clinical treatment.
Lyophilized material is usually kept cold and dry. After reconstitution, refrigerate and avoid repeated freeze-thaw cycles unless the protocol specifically calls for aliquots.
Primary animal studies often scale by body weight, whereas many secondary peptide-protocol charts use fixed absolute amounts. They are different reference frames and should not be mixed casually.
Read the research yourself
These references were validated against the NCBI database. No citation appears here unless it resolves to a real paper.
- Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications.PubMed
- Thymosin beta4 accelerates wound healing.PubMed
- Animal studies with thymosin beta, a multifunctional tissue repair and regeneration peptide.PubMed
- The regenerative peptide thymosin β4 accelerates the rate of dermal healing in preclinical animal models and in patients.PubMed
- A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers.PubMed